Dear Editor,
============

Exome sequencing of sporadic pancreatic neuroendocrine tumours (PNETs) has identified mutually exclusive mutations in the chromatin regulators α-thalassaemia/mental retardation X-linked *(ATRX)*and death-associated protein 6 *(DAXX)* genes in 43% of cases (18 and 23% of cases respectively in 68 cases studied) ([@bib2], [@bib6]). ATRX and DAXX are chromatin remodellers; their loss leads to alternative lengthening of telomeres (ALT) and chromosomal instability (CIN) ([@bib5]). ALT is a telomerase-independent mechanism for the maintenance of telomere stabilisation. Although it was initially reported that *ATRX/DAXX* mutant tumours had superior 10-year survival and outcome ([@bib6]), a recent larger study on 243 tumours demonstrated that ATRX and DAXX loss and associated ALT in PNETs correlates with CIN, advanced tumour stage, the development of metastases and poorer progression-free survival (PFS) and overall survival (OS) ([@bib7]).

ATRX interacts with DNA methyltransferases 3A and 3L (DNMT3A/3L), known as ATRX-DNMT3A-DNMT3L (ADD) ([@bib4]). DNMT3A and its accessory protein, DNMT3L, contain a histone H3 lysine 4 (H3K4) methyl-interacting ADD domain which links DNA methylation with unmodified H3K4. This interaction is one of the three described protein domains that provide a functional link between DNA methylation and histone modification. These interactions are pivotal for maintaining accurate replication of histone methylation patterns in newly replicated chromatin and in the subsequent fidelity of gene expression. ATRX interacts directly with DAXX, which functions as a chaperone for the deposition of the histone variant H3.3 at repeat sequences across the genome, including CpG islands and telomeric, pericentric and ribosomal repeats ([@bib1]). DAXX is a highly specific histone chaperone that discriminates H3.3 from other H3 variants. Mutually exclusive mutations in *ATRX*and *DAXX*are also found in neurological tumours, including neuroblastomas, paediatric glioblastomas, oligodendrogliomas and medulloblastomas ([@bib1]). Notably, H3.3 is mutated in paediatric glioblastoma and bone tumours, and H3.3 mutations are often associated with changes in global DNA methylation ([@bib9], [@bib8]).

Because of the known interaction between ATRX and DNMT3A/3L and the interplay between ATRX and DAXX, it is likely that PNETs with a loss of these tumour suppressor genes would have different genome-wide DNA methylation patterns as compared to those tumours that retain this function.

In this study, we sought to determine the genome-wide DNA methylation and copy number aberration profiles in ATRX/DAXX-positive and ATRX/DAXX-negative PNETs using the Infinium 450K HumanMethylation BeadArray (Illumina Inc., San Diego, CA, USA).

Only ATRX/DAXX-positive tumours and tumours with a loss of either ATRX or DAXX were considered. Included in the study were 12 age-matched, normal control pancreatic tissue samples (endocrine and exocrine) because of the extreme rarity of isolated pancreatic islet cell samples. Cases that showed heterogeneous ATRX or DAXX loss were also excluded so as to avoid difficulties in drawing firm conclusions.

In total, 53 formalin-fixed paraffin-embedded tumour specimens (46 primaries and seven liver metastases from 39 cases) were included in this study ([Fig. 1](#fig1){ref-type="fig"}A). Of these, 27 specimens (51%) had lost either ATRX (*n*=9; 33%) or DAXX (*n*=18; 67%) protein expression, as determined by immunohistochemistry (Anti-ATRX (SAB4502258) and Anti-DAXX (HPA008736) antibodies (both rabbit polyclonal) were provided by Sigma--Aldrich). Endothelial cells that stained positive for ATRX and DAXX served as the internal control in each immunochemistry section from cases that lacked expression of the corresponding protein. Seven of 26 (27%) low-grade primary tumours (G1, ki-67 of \<2%) exhibited ATRX/DAXX loss as compared to 13 of 19 (68%) intermediate-grade tumours (G2, ki-67 2--20%) (*P*=0.008, Fisher\'s exact test). One G3 and six of seven metastatic specimens also exhibited ATRX/DAXX loss.

Survival analysis was based on 34 cases with available follow-up data (eight ATRX-negative, nine DAXX-negative, and 17 ATRX/DAXX-positive cases; [Table 1](#tbl1){ref-type="table"}). Data were not available for two DAXX-negative and one ATRX/DAXX-positive case. Case 37 (counted twice), which had both ATRX-negative and ATRX/DAXX-positive samples, was also excluded. Analysis of the ATRX/DAXX-negative cases demonstrated that eight cases (five DAXX-negative and three ATRX-negative cases) progressed within 5 years of follow-up, whereas nine cases (four DAXX-negative and five ATRX-negative cases) did not. The majority of positive cases (13 of 17) remained progression-free over the period of study. Poorer 5-year PFS was observed in ATRX-negative and DAXX-negative cases as compared to ATRX/DAXX-positive cases (*P*=0.0009) ([Fig. 1](#fig1){ref-type="fig"}B). When ATRX-negative and DAXX-negative cases were analysed independently, a loss of DAXX led to a significantly poorer PFS at 5 years (DAXX loss: 16%, *P*=0.0005; ATRX loss: 52%, *P*=0.15; and no loss 85% 5-year PFS; [Fig. 1](#fig1){ref-type="fig"}C). All *P* values were obtained using a Cox regression model.

Depending on the different pair-wise comparisons, certain samples that had been assigned to unique arrays had to be removed to allow for the correction of the batch-to-batch variation which occurs when running the Illumina 450K HumMeth array. Comparison between all ATRX/DAXX-negative and ATRX/DAXX-positive tumours identified 58 methylation-variable positions (MVPs). Independent comparisons of either DAXX-negative (*n*=18) or ATRX-negative (*n*=7) with ATRX/DAXX-positive tumours (*n*=23) revealed 4352 MVPs and 34 differentially methylated regions (DMRs) and 258 MVPs and one DMR respectively. When ATRX-negative and DAXX-negative tumours were compared, we identified 196 195 MVPs and 6708 DMRs. Taken together, these observations demonstrate that genome-wide DNAm changes are associated with a loss of DAXX expression and not a loss of ATRX. A Benjamini--Hochberg (BH) adjusted *P* value of \<0.05 that corrected for multiple testing (false discovery rate) was used throughout the various comparisons in order to identify significantly methylated variable positions.

When ATRX-negative and DAXX-negative tumours were compared as one group to normal pancreatic samples, we identified 133 938 MVPs (BH adjusted *P* value \<0.05) and 4664 DMRs. A heat map that plotted the top 1000 MVPs for this comparison demonstrated that tumours were separated primarily by grade and then by ATRX or DAXX status ([Fig. 1](#fig1){ref-type="fig"}D). This was further confirmed by the unsupervised clustering of G2 tumours (eight DAXX-negative and five ATRX-negative cases) alone against normal pancreatic control samples for the top 1000 MVPs ([Fig. 1](#fig1){ref-type="fig"}E).

Of the 26 ATRX/DAXX-negative tumours ([Fig. 1](#fig1){ref-type="fig"}D), 20 samples (77%) were grouped into a distinct cluster. However, six ATRX/DAXX-negative tumour samples had intermediate methylation profiles and clustered with the normal control pancreatic samples ([Fig. 1](#fig1){ref-type="fig"}D). Of them, five were DAXX-negative (four G1 and one G2 tumours), and one was ATRX-negative (a G2 tumour). When comparing G2 tumours vs normal pancreas, there were 127 683 MVPs (adjusted *P* value \<0.05) and 4337 DMRs. However, for G1 vs normal pancreas, 31 480 MVPs and 300 DMRs were identified. This indicates that low-grade (G1) tumours and normal pancreas have similar methylation profiles.

Copy number variation (CNV) was determined in ATRX/DAXX-negative and ATRX/DAXX-positive tumours using DNA methylation data as previously described ([@bib3]). ATRX-negative and DAXX-negative tumours demonstrated increased CNV as compared to positive tumours ([Fig. 1](#fig1){ref-type="fig"}F). The genome-wide CNV rate was quantified by determining the cumulative size of genomic alterations (bp) in genomic regions that harboured a copy number change of \<−0.3 (for loss) or \>0.3 (for gain). Across the 23 ATRX/DAXX-positive primary tumours, there were 1.4×10^9^ bp of CNV in total (range per tumour 250 000--4.3×10^6^, median 1.6×10^6^). Across the 25 ATRX/DAXX-negative primary tumours, there were 2.4×10^9^ bp of CNV in total (range per tumour 279 000--8.0×10^7^, median 1.5×10^7^).

This is the first study of genome-wide DNA methylation in ATRX/DAXX-positive and ATRX/DAXX-negative PNETs. The finding of a higher incidence of ATRX and DAXX loss in intermediate-grade (G2) tumours may account for the worse PFS and OS previously observed ([@bib7]); however, this finding requires validation in a separate clinical cohort.

Genome-wide DNA methylation analysis identified significantly more MVPs in DAXX-negative vs ATRX/DAXX-positive tumours as compared to ATRX-negatives vs ATRX/DAXX-positive tumours (4352 and 258 respectively). This suggests that DAXX deficiency drives genome-wide methylation changes, potentially through the functional loss of H3.3 deposition (which binds DAXX in a highly specific manner and loads it into DNA, whereas ATRX is a co-factor that is involved in DAXX targeting chromatin) and also through binding with the maintenance DNA methyl transferase *DNMT1*([@bib9]). Mutations in H3.3 occur commonly in paediatric brain tumours ([@bib8]) and are known to lead genome-wide methylation changes. Because ATRX interacts with the *de novo*DNA methyl transferases DNMT3A/3L, its impact on genome-wide methylation in ATRX-deficient PNETs is less marked.

In addition to investigating genome-wide DNA methylation changes, CNV was determined from the non-normalised methylated and unmethylated signal intensities of the 450K array probes as previously described ([@bib3]). In keeping with previously reported data in PNETs ([@bib7]) and other solid tumours, we found a higher incidence of CNV alterations in tumours that had lost ATRX and DAXX ([@bib5]). We also demonstrated that ATRX/DAXX-negative tumours have a poorer PFS as compared to ATRX/DAXX-positive cases (30 vs 85%, *P*=0.0009) and that DAXX-negative tumours have the poorest 5-year PFS overall (16%, *P*=0.0005).

We demonstrated that even though they have mutually exclusive mutations, ATRX- and DAXX-deficient PNETs have distinct genome-wide DNA methylation profiles. Loss of DAXX and not ATRX appears to be the driver event in altering genome-wide methylation changes in PNETs. Previous studies have analysed PNETs with ATRX and DAXX loss in a single cohort, because mutations in these genes are predominantly mutually exclusive. These findings are also relevant to other neurological tumours which are driven by ATRX and DAXX loss.

Finally, we demonstrated that DAXX-negative tumours have the poorest 5-year PFS, and we therefore suggest more aggressive disease course. However, further validation of these findings is warranted in a separate clinical cohort.
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![(A) Details of the study cohort. (B and C) Kaplan--Meier survival curves for ATRX- and DAXX-negative cases (*n*=17) as compared to ATRX/DAXX-positive cases (*n*=17) and ATRX-negative (*n*=8) and DAXX-negative (*n*=9) cases analysed independently and compared to ATRX/DAXX-positives cases respectively. The 5-year PFS was 85% for positive cases, 52% for ATRX-negative cases and 16% for DAXX-negative cases. (D) Unsupervised cluster analysis using the top 1000 MVPs that showed segregation of ATRX-negative (in green) and DAXX-negative (in orange) tumours as compared to normal pancreatic tissue. Of the six ATRX/DAXX-negative tumour samples (from six cases) that clustered with the normal control pancreatic samples, only one case (G1, DAXX-negative) progressed (PFS 51 months), and two cases had no follow-up data. Of the six metastatic samples included in this study, two of them (both DAXX-negative) had a matched G1 tumour sample. One of them grouped tightly with the G1 primary tumour. DNA methylation values (*β*-value 0--1) are represented using a colour scale, where yellow=low methylation and blue=high methylation. Samples are shown on the *x*-axis, and probes are shown on the *y*-axis. (E) Confirmation of tumour segregation primarily by grade and then by ATRX*or*DAXX status using the top 1000 MVPs. (F) Copy number variation (CNV) profiles associated with low and intermediate PNETs. The top panel demonstrates increasing CNV across the genome for low-grade (G1, ki-67 \<2%) tumours, with the least CNV occurring in the ATRX/DAXX-positive primary (left). Increasing CNV alterations are seen in the ATRX/DAXX-negative tumour (middle) and most CNV alterations occur in the ATRX/DAXX-negative G1 liver metastasis (right). The same is observed in intermediate grade (G2, ki-67 3--20%) tumours in the bottom panel. Segmented copy numbers are shown as a red line, and sequential chromosomes are shown in green and black (chr. 1--22).](ERC150108f01){#fig1}

###### 

Clinical information and survival data

  **Patient ID**                   **Sample ID**   **Age**   **Gender**   **Primary/metastasis**   **Grade**   **Protein expression lost**   **Total follow-up (months)**   **PFS months**   **OS months**
  -------------------------------- --------------- --------- ------------ ------------------------ ----------- ----------------------------- ------------------------------ ---------------- ---------------
  **ATRX/DAXX-negative tumours**                                                                                                                                                             
   1                               1B2T_MG2_N      46        M            Metastasis               MG2         ATRX                          54                             51               54
   3                               3A28T2_G3_N     53        M            Primary                  G3          ATRX                          83                             14               83
   4                               4A4T_G2_N       60        M            Primary                  G2          DAXX                          85                             3                85
   7                               7C3T_MG1_N      81        F            Metastasis               MG1         ATRX                          60                             No progression   Alive
   8                               8A2T_G1_N       49        F            Primary                  G1          DAXX                          NA                             NA               NA
                                   8A3T1_G1_N                                                      G1          DAXX                                                                          
                                   8A3T2_G1_N                                                      G1          DAXX                                                                          
   11                              11A1T_MG3_N     56        M            Metastasis               MG3         DAXX                          20                             16               20
   12                              12A3T1_MG2_N    62        F            Metastasis               MG2         DAXX                          106                            29               Alive
                                   12A9T2_MG2_N                           Metastasis               MG2         DAXX                                                                          
                                   12A10T_G2_N                            Primary                  G2          DAXX                                                                          
   13                              13A12T_G2_N     73        M            Primary                  G2          DAXX                          55                             15               Alive
                                   13A13T_G2_N                                                     G2          DAXX                                                                          
                                   13A14T_G2_N                                                     G2          DAXX                                                                          
                                   13A19T_G2_N                                                     G2          DAXX                                                                          
   15                              15A6T_G1_N      36        M            Primary                  G1          DAXX                          39                             No progression   Alive
   19                              19A7T_G1_N      30        F            Primary                  G1          DAXX                          54                             51               54
   21                              21A4T_G2_N      66        M            Primary                  G2          ATRX                          39                             No progression   Alive
   25                              25A3T_G1_N      72        F            Primary                  G1          DAXX                          34                             No progression   Alive
   26                              26A2T_G2_N      21        M            Primary                  G2          DAXX                          21                             No progression   Alive
   30                              30C6T_G2_N      54        M            Primary                  G2          ATRX                          40                             No progression   Alive
   31                              31A4T_G2_N      74        F            Primary                  G2          ATRX                          24                             No progression   Alive
   34                              34A10T_G2_N     69        F            Primary                  G2          DAXX                          NA                             NA               NA
   35                              35A7T_G1_N      23        F            Primary                  G1          DAXX                          56                             No progression   Alive
   36                              36A3T_G2_N      57        M            Primary                  G2          ATRX                          72                             14               72
   37                              37A3T1_G2_N     40        F            Primary                  G2          ATRX                          49                             No progression   Alive
   38                              38A4T_MG1_N     84        F            Metastasis               MG1         ATRX                          66                             No progression   Alive
  **ATRX/DAXX-positive tumours**                                                                                                                                                             
   2                               2B2T_G1_P       67        M            Primary                  G1          No Loss                       90                             No progression   Alive
   5                               5B5T2_G1_P      60        M            Primary                  G1          No Loss                       84                             18               Alive
   6                               6A6T_G1_P       51        F            Primary                  G1          No Loss                       68                             No progression   Alive
                                   6A8T1_G1_P                                                      G1          No Loss                                                                       
                                   6A8T2_G1_P                                                      G1          No Loss                                                                       
                                   6A8T3_G1_P                                                      G1          No Loss                                                                       
   9                               9A9T2_G1_P      62        F            Primary                  G1          No Loss                       70                             No progression   Alive
   10                              10A7T_G1_P      45        F            Primary                  G1          No Loss                       54                             No progression   Alive
   14                              14B8T_G1_P      NA        NA           Primary                  G1          No Loss                       45                             No progression   Alive
   17                              17A2T_G1_P      53        F            Primary                  G1          No Loss                       47                             No progression   Alive
                                   17A4T_G1_P                                                      G1          No Loss                                                                       
   18                              18A4T_G1_P      64        F            Primary                  G1          No Loss                       40                             No progression   Alive
                                   18A5T_G1_P                                                      G1          No Loss                                                                       
   20                              20A3T_MG2_P     69        F            Metastasis               MG2         No Loss                       NA                             NA               NA
   22                              22A6T_G1_P      72        M            Primary                  G1          No Loss                       18                             No progression   Alive
   23                              23D2T_G1_P      54        F            Primary                  G1          No Loss                       28                             No progression   Alive
                                   23D7T_G1_P                                                      G1          No Loss                                                                       
   24                              24A6T2_G2_P     47        F            Primary                  G2          No Loss                       84                             36               Alive
   27                              27A6T_G2_P      58        M            Primary                  G2          No Loss                       33                             No progression   Alive
   28                              28A8T_G2_P      66        F            Primary                  G2          No Loss                       18                             No progression   Alive
   29                              29C4T_G1_P      71        F            Primary                  G1          No Loss                       26                             No progression   Alive
   32                              32B4T_G1_P      26        M            Primary                  G1          No Loss                       126                            120              Alive
   33                              33E13T_G1_P     58        M            Primary                  G1          No Loss                       26                             No progression   Alive
   37                              37A4T_G2_P      40        F            Primary                  G2          No Loss                       49                             No progression   Alive
                                   37A5T_G2_P                                                      G2          No Loss                                                                       
   39                              39IIFT_G2_P     58        F            Primary                  G2          No Loss                       162                            36               Alive

PFS, progression-free survival; OS, overall survival; NA, not available. The three samples from case 37 are different regions of the same surgical pathological specimen. However, because of intra-tumoral heterogeneity, we observed that one sample was ATRX-negative, whereas the remaining two were ATRX/DAXX-positive. For this reason, case 37 was not considered in the survival analysis.
